Prevention Of Contrast-Induced Nephropathy With Jiawei Wendan Decoction In Patients With Coronary Heart Disease Undergoing Coronary Artery Intervention

Objective:To evaluate the safety and efficacy of Jiawei Wendan decoction inprevention of contrast-induced nephropathy(CIN) in patients with coronary heart diseaseundergoing coronary angiography(CAG)and/or Percutaneous Coronary Intervention(PCI).Methods:A single-center prospective randomized controlled trial was performed,inwhich80CHD patients undergoing CAG and/or PCI were divided randomly into thecontrol group(n=40) and the intervention group(n=40).Both groups received routinetreatment including anti-platelet therapy,anti-coagulation therapy,coronary arterydilation,lipid adjusting,and hydration while the intervention group received additionalJiawei Wendan decoction from two days before until three days after the procedure.Serumcreatinine(Scr) was checked at baseline,24hours and72hours after CAG and/or PCI.eGFRwas calculated according to modified MDRD formula.Incidence rates of CIN werecompared between the two groups.Results:Incidence rates of CIN didn’t significantly vary between the control groupand the intervention group[10.0%(4cases)vs2.5%(1cases),P>0.05].Levels of SCr andeGFR showed no significant differences between the two groups(P>0.05).Conclusion:Jiawei Wendan decoction is ineffective in the prevention of CIN in CHDpatients undergoing CAG and/or PCI.